PHI with C1 inhibitor deficiency
How does this condition affect your private health insurance?
C1 Inaktivatormangel, also known as Hereditary Angioedema (HAE), is a rare genetic disorder caused by a deficiency or dysfunction of the C1 esterase inhibitor protein. This protein normally regulates parts of the immune system and coagulation pathways. Its absence leads to uncontrolled production of bradykinin, a potent vasodilator, resulting in recurrent, unpredictable episodes of severe swelling. These attacks can affect the skin, gastrointestinal tract, and upper airways, causing disfigurement, intense pain, and potentially life-threatening laryngeal edema. The disease is chronic, requiring lifelong management to prevent or mitigate attacks and improve quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Typically 2-5 days for an acute attack without effective treatment.
Duration of Illness (Lifetime)
Chronic, lifelong disease with recurrent, unpredictable attacks.
Cost of Treatment (Initial)
Thousands to tens of thousands of dollars for an acute attack requiring emergency care and specific C1-INH replacement therapy.
Cost of Treatment (Lifetime)
Extremely high, often hundreds of thousands to millions of dollars due to the need for long-term prophylactic and on-demand therapies.
Mortality Rate
Low with timely diagnosis and appropriate treatment. However, untreated laryngeal edema carries a significant risk of asphyxiation (15-33%).
Risk of Secondary Damages
High. Includes chronic pain, anxiety, depression, social isolation, and significant impact on quality of life and productivity.
Probability of Full Recovery
Extremely low to none. It is a genetic disorder with no cure; management focuses on preventing and treating attacks.
Underlying Disease Risk
Low for the hereditary form. Acquired C1-INH deficiency can be associated with lymphoproliferative disorders or autoimmune diseases.